Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history

Semin Arthritis Rheum. 2014 Jun;43(6):751-8. doi: 10.1016/j.semarthrit.2013.11.007. Epub 2013 Nov 13.

Abstract

Objectives: The coexistence of systemic lupus erythematosus (SLE) and multiple sclerosis (MS) in the same individual has rarely been described. Our objective was to report on the prevalence, clinical characteristics, and prognosis of cases fulfilling the criteria for both SLE and MS.

Methods: We utilized existing patient cohorts from the Departments of Rheumatology and Neurology, University of Crete, and screened patients diagnosed with either SLE (n = 728) or MS (n = 819) for features of both diseases. The clinical, laboratory, and neuroimaging findings were assessed.

Results: We identified nine patients who fulfilled the diagnostic criteria for both SLE and MS, corresponding to a prevalence rate of 1.0-1.2% in each cohort. All patients were women, with an average age at SLE diagnosis of 42.1 years (range: 34-56 years). The diagnosis of SLE preceded the development of MS in five patients, with a time lag ≤ 5 years in four of them. Initial presentation of MS included spinal symptoms in seven patients. All patients had features of mild SLE with predominantly cutaneous, mucosal, and musculoskeletal manifestations. Accordingly, therapeutic decisions were mainly guided by the severity of the neurological syndrome. During the median follow-up of 4 years (range: 1-10 years), three patients remained stable and the remaining experienced gradual deterioration in their neurological status. SLE remained quiescent in all patients while on standard immunomodulatory MS therapy.

Conclusions: Occurrence of both diseases in the same individual is rare, corroborating data that suggest distinct molecular signatures. SLE and MS coexistence was not associated with a severe phenotype for either entity.

Keywords: Coexistence; Multiple sclerosis; Natural history; Systemic lupus erythematosus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Azathioprine / therapeutic use
  • Comorbidity
  • Female
  • Glatiramer Acetate
  • Greece / epidemiology
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunologic Factors / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Interferon-beta / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / epidemiology*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / epidemiology*
  • Natalizumab
  • Peptides / therapeutic use
  • Prevalence
  • Rituximab

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunologic Factors
  • Immunosuppressive Agents
  • Natalizumab
  • Peptides
  • Rituximab
  • Hydroxychloroquine
  • Glatiramer Acetate
  • Interferon-beta
  • Azathioprine
  • Methotrexate